Merck & Co’s Keytruda Gets Foot In The Door For First-Line Gastric Cancer

 
• By Alexandra Shimmings

Results presented as ASCO from the mixed KEYNOTE-062 study suggest a place for pembrolizumab in first-line gastric cancer but data from other ongoing trials will be needed to support filings amid looming competition from Opdivo.

Chicago
All roads lead to Chicago and ASCO for oncologists • Source: Shutterstock

More from ASCO

More from Conferences